陕西盘龙药业集团股份有限公司 2024 年度独立董事述职报告 本人作为陕西盘龙药业集团股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》《上市公司独立董事管理办法》《公司章程》《独立董事工作 制度》等法律法规及制度的要求，始终秉持忠实、勤勉、尽责的职业准则，履行 独董职责，主动了解公司经营状况，认真审议董事会各项议案，独立客观发表专 业意见，充分发挥独立董事的作用，为公司规范运作和健康发展提供专业支持， 切实维护公司整体利益和全体股东尤其是中小股东的合法权益。本人 2024 年履 职情况报告如下： 一、 基本情况 1、独立董事基本情况 牛晓峰，1966 年 5 月出生，男，中国国籍，无境外永久居留权，博士，九三 学社社员，博士研究生导师，现工作于西安交通大学药学院。1986 年毕业于西安 医科大学药学院药学专业；1998 年获得西安交通大学生药学硕士学位；2007 年 获得西安交通大学药物分析学博士学位。主要研究方向为中药物质基础分析及中 药品质评价，中药材加工及中药新药、保健食品研制。现任陕西商洛秦药研究院 院长，中医药 ...

陕西盘龙药业集团股份有限公司 2024 年度独立董事述职报告 本人作为陕西盘龙药业集团股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》《上市公司独立董事管理办法》《公司章程》《独立董事工作 制度》等法律法规及制度的要求，始终秉持忠实、勤勉、尽责的职业准则，履行 独董职责，主动了解公司经营状况，认真审议董事会各项议案，独立客观发表专 业意见，充分发挥独立董事的作用，为公司规范运作和健康发展提供专业支持， 切实维护公司整体利益和全体股东尤其是中小股东的合法权益。本人 2024 年履 职情况报告如下： 一、 基本情况 1、独立董事基本情况 任海云，1974 年 11 月出生，女，汉族，中国国籍，无永久境外居留权，管 理学博士，经济学博士后，注册会计师，现任陕西师范大学国际商学院教授，博 士生导师，财务与会计系系主任。1997 年 7 月毕业于西北农林科技大学，被授 予经济学学士学位；2005 年 7 月毕业于西安交通大学，被授予管理学硕士学位； 2010 年 7 月毕业于西北大学，被授予管理学博士学位。1997 年 7 月-2 ...

焦磊鹏，1983 年 2 月出生，男，中国国籍，中共党员，无永久境外居留权， 中共党员，硕士学历，获得司法考试 A 证、证券从业资格证，西安市第十五届政 协委员，陕西省司法厅行政规范性文件合法性审核和备案审查专家库成员。历任 广州市公安局交警支队民警、陕西省人民检察院检察官、北京市博儒（西安）律 师事务所高级顾问，现任陕西盘龙药业集团股份有限公司独立董事、广东卓建（西 安）律师事务所律师。 2、符合独立董事独立性的规定 本人作为我公司的独立董事，任职期内本人未在公司担任除独立董事以外的 任何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不 存在利害关系或其他可能妨碍本人进行独立客观判断的关系，本人任职符合《上 市公司独立董事管理办法》等规定的独立性要求，不存在影响独立性的情形。 二、本人今年履职概况 1 2024 年度独立董事述职报告 本人作为陕西盘龙药业集团股份有限公司（以下简称"公司"）的独立董事， 严格按照《公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》《上市公司独立董事管理办法》《公司章程》《独立董事工作 制度》等法律法规及制度的要求，始终秉持忠实 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 1.1500 | 1.1500 | 0 | 1.1800 | | 每股净资产（元） | 15.39 | 14.58 | 5.56 | 10.15 | | 每股公积金(元) | 7.68 | 7.69 | -0.13 | 2.99 | | 每股未分配利润(元) | 6.21 | 5.40 | 15 | 5.68 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 9.74 | 9.81 | -0.71 | 9.74 | | 净利润(亿元) | 1.2 | 1.1 | 9.09 | 1.01 | | 净资产收益率(%) | 7.56 | 9.04 | -16.37 | 11.62 | | 名称 | 持有数量(万股) | 占总股本 | 增减情况 | | --- | --- | --- | --- | | | | 比例(%) | (万股) | | 谢晓林 ...

Financial Performance - The company reported a double-digit growth in sales revenue, with a significant increase in its main products, indicating a robust performance in the past year[7]. - The company's operating revenue for 2024 is approximately ¥973.86 million, a decrease of 0.71% compared to ¥980.83 million in 2023[24]. - Net profit attributable to shareholders for 2024 is approximately ¥120.27 million, an increase of 8.91% from ¥110.43 million in 2023[24]. - The net cash flow from operating activities for 2024 is approximately ¥156.59 million, representing a significant increase of 50.50% compared to ¥104.05 million in 2023[24]. - Total assets at the end of 2024 amount to approximately ¥2.28 billion, reflecting a growth of 7.29% from ¥2.13 billion at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 are approximately ¥1.64 billion, an increase of 5.56% from ¥1.55 billion at the end of 2023[24]. - Basic earnings per share for 2024 remain stable at ¥1.15, unchanged from 2023[24]. - The diluted earnings per share for 2024 is ¥1.15, an increase of 1.77% from ¥1.13 in 2023[24]. - The weighted average return on equity for 2024 is 7.56%, down from 9.04% in 2023[24]. - The company reported a quarterly revenue of approximately ¥261.57 million in Q3 2024, showing a steady performance[28]. Product Development and Innovation - The company successfully registered 211 varieties of formula granules, marking a breakthrough from zero to market entry[7]. - The company is focusing on innovation, with accelerated clinical exploration of its self-developed traditional Chinese medicine PLZY-001 and successful completion of pilot tests for several chemical generic drugs[9]. - The strategic goal is to establish a leading brand in the treatment of rheumatism and bone injuries, with a clear product pipeline that includes both oral and external applications[9]. - The company aims to implement a "21355" product cultivation target to drive innovation and development in key therapeutic areas[12]. - The company is focused on expanding its market presence and enhancing its product lineup, including proprietary health products and functional health foods[44]. - The company has established a diversified R&D system focusing on high-end new drug development, with multiple research centers and partnerships with top universities and research institutions[78]. - The company is accelerating the development of new products such as PLJT-001, PLJT-002, PLJT-003, and PLJT-004, aiming to create a comprehensive product pipeline[79]. - The company aims to develop over 400 products in the traditional Chinese medicine formula granules category, with 211 national standard varieties already developed[115]. Market Strategy and Expansion - The company aims to enhance its governance level through a comprehensive "one center, four platforms" R&D system and improve production quality through digital management[12]. - The company plans to implement a "21355" product cultivation target to drive innovation and development in key therapeutic areas[12]. - The company is focusing on a three-pronged development model: "policy decoding, innovation transformation, and ecological empowerment" to enhance its market position[35]. - The company has established a marketing network in 30 provinces, with over 630 pharmaceutical companies and coverage in more than 4,800 hospitals and 7,000 pharmacies[81]. - The company is actively involved in the development of new technologies and products, aiming to strengthen its competitive position in the pharmaceutical industry[44]. - The company has established a market expansion strategy that includes developing untapped county-level markets for its products[148]. Social Responsibility and Community Engagement - The company is committed to social responsibility, engaging in various initiatives from medical supply support to rural revitalization[11]. - The company is actively participating in social responsibility initiatives, including rural revitalization and public welfare activities[144]. - The company expressed gratitude to investors and partners, emphasizing the importance of community support in its growth journey[11]. Governance and Compliance - The company has established a complete and independent governance structure, ensuring compliance with relevant laws and regulations[154]. - The board of directors consists of nine members, including three independent directors, meeting legal requirements[157]. - The company has implemented a robust internal control system, with the audit department conducting audits to ensure compliance with regulations[163]. - The company maintains a clear separation from its controlling shareholder in terms of business, personnel, assets, and finance, ensuring independent operations[166]. - The company has a complete set of assets necessary for production and operations, including land use rights and equipment[167]. Financial Management and Investments - The company has received multiple awards for its products, including recognition as a top brand in the category of common household medications for rheumatic bone diseases[76]. - The company has received administrative regulatory measures from the China Securities Regulatory Commission in January 2024[194]. - The total amount of funds raised in 2023 through a private placement was ¥294.84 million, with a net amount of ¥294.84 million after deducting issuance costs[127]. - The total amount of funds raised in 2022 through public convertible bonds was ¥271.98 million, with a net amount of ¥271.98 million after deducting issuance costs[128]. - The cumulative amount of raised funds used by the end of 2024 is ¥276.09 million, with ¥300.53 million remaining unused[128]. - The company has committed to several investment projects, including a project in Shaanxi Province with a total investment of ¥15 million[130]. Human Resources and Employee Engagement - The company is enhancing employee care through a comprehensive 360-degree employee care system, promoting a culture of happiness and productivity[145]. - The number of R&D personnel increased by 8.70% from 69 in 2023 to 75 in 2024, with R&D personnel accounting for 11.05% of the total workforce[117]. - The company’s remuneration system for directors and senior management is linked to performance and individual capabilities[196]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue increase of 25% based on current market trends and user acquisition strategies[3]. - Future guidance includes maintaining a net profit margin of at least 15% while continuing to invest in growth initiatives[10]. - The company has outlined a future revenue guidance of 300 million for the next fiscal year, representing an expected growth of 9.2%[175].

Revenue and Profit - The company's revenue for Q1 2025 reached ¥250,212,341.68, representing a 19.08% increase compared to ¥210,115,513.50 in the same period last year[4] - Net profit attributable to shareholders was ¥31,249,274.14, a slight increase of 0.33% from ¥31,147,203.65 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥28,752,863.99, up 18.60% from ¥24,243,406.05 in the previous year[4] - Operating profit for the current period was ¥36,225,272.10, which is a 18.66% increase from ¥30,662,113.08 in the previous period[22] - Net profit for the current period was ¥31,165,841.97, slightly up from ¥31,057,891.33 in the previous period, reflecting a growth of 0.35%[22] Cash Flow - The net cash flow from operating activities decreased significantly by 59.10% to ¥25,964,726.12 from ¥63,478,364.28 in the same period last year[4] - Total cash inflow from operating activities amounted to $281,363,514.11, up from $271,946,168.16, reflecting a growth of 4.9%[26] - Cash outflow from operating activities increased to $255,398,787.99, compared to $208,467,803.88, representing a rise of 22.5%[26] - Cash flow from investing activities showed a net outflow of $22,733,672.35, improving from a net outflow of $47,176,845.97 in the previous period[26] - Cash inflow from financing activities decreased to $50,000,000.00 from $150,000,000.00, a decline of 66.7%[26] - Net cash flow from financing activities was -$6,907,331.39, compared to a positive cash flow of $49,220,138.89 previously[26] - The net increase in cash and cash equivalents was -$3,676,277.62, contrasting with a significant increase of $65,521,657.20 in the prior period[26] Assets and Liabilities - Total assets as of March 31, 2025, were ¥2,316,193,397.43, reflecting a 1.59% increase from ¥2,280,023,009.54 at the end of the previous year[4] - The company's current assets totaled RMB 1,809,097,800.40, compared to RMB 1,771,523,291.39 at the beginning of the period[17] - Total liabilities increased to ¥652,769,648.72 from ¥642,840,255.08, marking a rise of 1.44%[22] - The company’s total liabilities included short-term borrowings of RMB 50,000,000.00, unchanged from the previous period[18] - The company reported a significant increase in contract liabilities by 257.42% to ¥13,136,495.48, primarily due to an increase in advance payments received[7] Inventory and Expenses - The company's inventory increased by 18.35% to ¥113,127,828.48, attributed to higher sales of traditional Chinese medicine products[7] - Research and development expenses rose by 24.87% to ¥4,642,275.19, indicating increased investment in R&D activities[8] - Total operating costs amounted to ¥213,738,632.71, up 19.25% from ¥179,227,823.40 in the prior period[22] - Research and development expenses for the current period were ¥4,642,275.19, up from ¥3,717,714.19 in the previous period, indicating a growth of 24.88%[22] Shareholder Actions - The company completed a share buyback, repurchasing 373,500 shares, which is 0.35% of the total share capital, with a total transaction amount of RMB 10,002,880.25[13] - The share buyback was conducted at a price range between RMB 25.71 and RMB 28.50 per share, with a total planned expenditure between RMB 10 million and RMB 20 million[13] Project Updates - The company decided to terminate the "Shaanxi Province Medical Institution Preparation Center Construction Project" due to lower than expected market size and will use the remaining raised funds to permanently supplement working capital[15] Accounting and Auditing - The company did not undergo an audit for the first quarter report[27] - The new accounting standards will be first implemented starting in 2025[28]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-011 陕西盘龙药业集团股份有限公司 关于公司《药品生产许可证》变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于近期完成了《药品生 产许可证》的变更登记并取得了陕西省药品监督管理局换发的《药品生产许可证》， 同意公司《药品生产许可证》副本新增车间和生产线情况。现将相关情况公告如下： 一、《药品生产许可证》的基本情况 企业名称：陕西盘龙药业集团股份有限公司 注册地址：陕西省商洛市柞水县盘龙生态产业园 社会信用代码：91610000223472005U 法定代表人：谢晓林 企业负责人：谢晓林 质量负责人：徐远涛 生产负责人：孟重 有效期至：2025 年 12 月 16 日 | 生产地址 | 车间 | 生产线 | 范围 | | --- | --- | --- | --- | | 陕西柞水盘龙 | 中药配方颗粒车 | 中药配方颗粒生 | 中药饮片(【净制、切制、 | | 生态产业园 | 间 | 产线 | 炒制(清炒、麸炒、砂炒)、 | | | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 陕西盘龙药业集团股份有限公司（以下简称"公司"）第四届董事会第二十 三次会议通知于 2025 年 3 月 18 日以邮件、电话方式通知各位董事。本次会议于 2025 年 3 月 21 日在西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医 药股份有限公司二楼会议室采用现场与通讯相结合方式召开。会议应出席董事 9 名，实际出席董事 9 名（其中任海云女士、牛晓峰先生、焦磊鹏先生以通讯方式 出席本次会议）。会议由公司董事长谢晓林先生召集并主持，公司监事及高级管 理人员列席了本次会议。本次会议的召集和召开均符合《中华人民共和国公司法》 等有关法律法规及《陕西盘龙药业集团股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议并通过了《关于向中国农业银行股份有限公司柞水县支行申请一亿 元短期流动资金贷款暨公司实际控制人提供担保的议案》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 公司因发展需要拟加强与金融机构的合作，计划向中国农业银行股份有限公 司柞水县支行申请不超 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-009 陕西盘龙药业集团股份有限公司 关于注销部分募集资金账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、2022 年度可转换公司债券募集资金 经中国证券监督管理委员会许可[2021]3323 号核准，公司于 2022 年 3 月 3 日发行可转换公司债券 276 万张，每张面值为人民币 100 元，发行价为每张人民 币 100 元，募集资金总额为人民币 276,000,000.00 元，已由承销机构中泰证券股 份有限公司于 2022 年 3 月 9 日汇入公司开立在招商银行西安分行曲江支行账号 为 129907180410909 的银行账户 150,625,400.00 元，开立在中国银行西安太白小 区支行账号为 102498736801 的银行账户 49,568,400.00 元，开立在上海浦东发展 银行股份有 限 公 司 西 安 分 行 账 号 为 72010078801600005471 的银行账户 73,825,067.92 元，共汇入人民币 274,018,867.92 ...